[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 3, Issue 2 (Autumn-winter 2015-2016 2015) ::
Jorjani Biomed J 2015, 3(2): 14-25 Back to browse issues page
Preferential expression of CD200 and Indoleamine 2, 3-dioxygenase-1 (IDO-1) in Acute Myeloid Leukemia Patients with Relapse
Ali Memarian , Sara Abdolmaleki
Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran , alimemarian@goums.ac.ir
Abstract:   (2359 Views)

Background & Objectives: Defect in Immune responses, such as immunosuppression is one of the major causes of AML pathogenesis and progression which could be targeted for immunotherapy of these patients. CD200 and IDO are immunoregulatory factors which are overexpressed in some solid tumors and hematological malignancies. Distinct researches have shown that CD200 and IDO expressions are associated with AML progression. In the current study, we simultaneously examined the expression of these molecules, as the two important factors including in immunosuppression, in the newly diagnosed and relapse AML patients to investigate their correlation with each other.

Methods: In this study, 48 Peripheral Blood Mononuclear Cells (PBMCs) samples of newly diagnosed and relapsed AML patients were tested and also 32 PBMCs of normal subjects were employed as normal controls. CD200 expression level was examined on the cells by Flowcytometry and quantitative real time RT-PCR was used to determine the IDO-1 gene expression. Finally data were analyzed statistically by Spss 17 software.

Results: Our data showed that CD200 (P=0.02) and IDO-1 (P=0.44) were overexpressed in AML samples especially in relapsed patients. Comparison between FAB AML subgroups demonstrated no statistical differences regarding CD200 level but expression of IDO-1 was slightly increased only in M4 subgroup in comparison to M3 (P=0.01). Correlation analyses showed strong association between the expressions of CD200 and IDO-1 in all patients particularly in relapsed AML, whereas no significant correlation was found in normal subjects.  

Conclusion: According to the role and overexpression of CD200 and IDO-1 in AML patients and also their two-way correlation with T-reg lymphocytes in disease induction and progression, simultaneous assessment of these parameters are so valuable for more exact prognosis detection. Also inhibition of all these immunoregulatory pathways could be so useful for immunotherapy outcome, especially in relapsed AML. 

Keywords: Acute Myeloid Leukemia, CD200, IDO, Immunosuppression, Disease Progression, Relapse
Full-Text [PDF 818 kb]   (662 Downloads)    
Type of Study: Original paper | Subject: General
Received: 2016/03/19 | Accepted: 2016/03/19 | Published: 2016/03/19
Send email to the article author

Add your comments about this article
Your username or Email:

Write the security code in the box >

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Memarian A, Abdolmaleki S. Preferential expression of CD200 and Indoleamine 2, 3-dioxygenase-1 (IDO-1) in Acute Myeloid Leukemia Patients with Relapse . Jorjani Biomed J. 2015; 3 (2) :14-25
URL: http://goums.ac.ir/jorjanijournal/article-1-403-en.html

Volume 3, Issue 2 (Autumn-winter 2015-2016 2015) Back to browse issues page
مجله زیست پزشکی جرجانی Jorjani Biomedicine Journal
Persian site map - English site map - Created in 0.051 seconds with 803 queries by yektaweb 3603